no covering letter

9703389-8

RTMP'S copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 305/14, C07F 7/18, C07D 493/10, 263/04, A61K 31/335 — A1

(11) International Publication Number: WO 96/29321

(43) International Publication Date: 26 September 1996 (26.09.96)

(21) International Application Number: PCT/EP96/00904

(22) International Filing Date: 4 March 1996 (04.03.96)

(30) Priority Data:
MI95A000533 17 March 1995 (17.03.95) IT

(71) Applicant (*for all designated States except US*): INDENA S.P.A. [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BOMBARDELLI, Ezio [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT). DE BELLIS, Paolo [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT). GABETTA, Bruno [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).

(74) Agent: MINOJA, Fabrizio; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: 10-DEACETYLBACCATINE III AND 10-DEACETYL 14β-HYDROXYBACCATINE III DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

(57) Abstract

The present invention relates to novel derivatives of 10-deacetylbaccatine III and of 10-deacetyl-14β-hydroxybaccatine III, having cytoxic and anti-tumoral activity. They are prepared starting from the so-called syntons or from other taxanes of natural origin, by selective oxidation of the hydroxyl in position 10 to keto function and subsequent esterification in position 13, if necessary, with isoserine chains variously substituted. The products of the invention can be administered by injection or orally, when suitably formulated.